BOS
AGIO icon

Bingham Osborn & Scarborough’s Agios Pharmaceuticals AGIO Stock Holding History

Bingham Osborn & Scarborough’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,941
Closed -$738K – 147
2019
Q1 		$738K Buy
+10,941
New +$637K 0.07% 68

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bingham Osborn & Scarborough's AGIO Position: Q2 2019 in Review

Bingham Osborn & Scarborough sold out of Agios Pharmaceuticals (AGIO) in Q2 2019, closing a stake of 10,941 shares — an estimated $738K sold.

Bingham Osborn & Scarborough first reported a position in AGIO in Q1 2019 and held it in 1 quarter. The position peaked at $738K in Q1 2019. 189 funds tracked by Wall St. Rank hold AGIO as of Q2 2019.

  • Bingham Osborn & Scarborough reported no remaining Agios Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Bingham Osborn & Scarborough sold 10,941 Agios Pharmaceuticals shares in Q2 2019, an estimated $738K.
  • Bingham Osborn & Scarborough first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Bingham Osborn & Scarborough's Agios Pharmaceuticals position peaked at $738K in Q1 2019.
  • 189 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2019.

Based on Bingham Osborn & Scarborough's 13F filing for Q2 2019, filed 2 Aug 2019.